Literature DB >> 21278770

Hematology in 2010: New therapies and standard of care in oncology.

Vincent T DeVita1, George P Canellos.   

Abstract

2010 was not a year of survival breakthroughs in hematologic malignancies. However, in Hodgkin's disease and multiple myeloma new therapies emerged as the standard of care and nilotinib may be considered the treatment choice for newly diagnosed chronic myeloid leukemia.

Entities:  

Mesh：

Year:  2011        PMID： 21278770     DOI： 10.1038/nrclinonc.2010.221

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  6 in total

1.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

2.  Hematology: Bortezomib and dexamethasone induction for multiple myeloma.

Authors:  Jacob Laubach; Paul Richardson
Journal:  Nat Rev Clin Oncol       Date:  2011-01       Impact factor: 66.675

3.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

5.  Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.

Authors:  George P Canellos; Jeremy S Abramson; David C Fisher; Ann S LaCasce
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245
  6 in total
  2 in total

Review 1.  Interventional Oncology Service Development.

Authors:  Samdeep Mouli; Jennifer C Baker; Daniel B Brown
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 2.  Honokiol: A Review of Its Anticancer Potential and Mechanisms.

Authors:  Chon Phin Ong; Wai Leong Lee; Yin Quan Tang; Wei Hsum Yap
Journal:  Cancers (Basel)       Date:  2019-12-22       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.